

CV AZZAM A. MAGHAZACHI

Email: azzammaghazachi@yahoo.com or amagazachi@sharjah.ac.ae

Citizen

CANADIAN

Research Interests

Autoimmune diseases

Immunology

Chemokines

Cancer

Drug mechanisms of action (MOA)

Education

•1984 Ph.D. Department of Immunology, University of Manitoba Medical School, Canada

•1976 MS. Department of Microbiology, New York University Medical School, USA

Membership in professional societies

- American Society for Biochemistry and Molecular Biology
- American Association of Immunologists
- Society for Leukocyte Biology
- FASEB
- American Association for Cancer Research

Teaching experience

•2016-present: Teach 1st, 2nd and 3rd year Immunology course to medical students, University of Sharjah, Sharjah, UAE.

•2016-present: Prepared the Immunology curriculum for medical college at the University of Sharjah

•2007-2015: Taught the practical Blood course, Faculty of Medicine, to the third year medical students, University of Oslo, Norway. This course teaches students how to withdraw blood from the veins, and how to perform practical tasks such as measuring hemoglobin, PCV, MCV, hematocrit and other hematological and microbiological tests. This include testing gram positive and gram negative bacteria, and how to detect for viruses in the plasma collected from students. It also teaches students how to differentially recognize and count various blood cells including neutrophils, eosinophils, monocytes, lymphocytes and basophils.

•2007-2015: Taught the courses of Immunology, Microbiology and Hematology to the 3rd year medical students at the University of Oslo. Norway.

•1991-1995: Taught several immunology and biochemistry courses to undergraduate students, Department of Biochemistry, Laurentian University, Canada.

•1991-1995: Taught Microbiology courses, Department of Microbiology and Immunology, University of Ottawa, Canada.

Member of Editorial Board

- Editor: Frontiers in Immunology Special Issue: Immunomodulatory effects of drugs for treatment of multiple sclerosis and other immune-related diseases.
- Member of editorial board: Toxins
- Member of editorial board: British Journal of Medicine and Medical Research
- Member of editorial board: American Journal of Molecular Biology
- Member of editorial board: ImmunoTargets and Therapy
- Associate editor: International Journal of Medical and Clinical Research
- Member of editorial board: Open Journal of Immunology
- Editor: MOJ Immunology
- Editor-in-chief: Advances in Neuroscience Research
- Associate editor-in-chief: Frontiers in Clinical Medicine
- Editorial board member: Trends in Molecular Biology
- Member of editorial board: Journal of Biological Medicine

Academic positions:

- Currently Professor, College of Medicine, and Sharjah Institute for Medical Research, Sharjah University, Sharjah, UAE. Assistant Dean for Graduate Studies, College of Medicine, University of Sharjah
- 2007-2015: Professor, Department of Physiology, University of Oslo, Norway
 - 2004-2007: CSO and Executive Director of Research, Bio-Quant, Inc., San Diego, CA, USA
 - 1997-2004: Senior Scientist, Department of Anatomy, University of Oslo
 - 1995-1997: Visiting Scientist, Laboratory of Immunobiology, Department of Anatomy, University of Oslo, Norway
 - 1991-1995: Career Scientist, Northeastern Ontario Regional Cancer Centre, Ontario Cancer Foundation, Ontario, Canada
Adjunct Professor, Department of Chemistry/Biochemistry, Laurentian University, Sudbury, Ontario, Canada
 - 1991-1996: Assistant/Associate Professor, Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
 - 1988-1991: Project Leader, Molecular Immunology Section, Biotechnology Research Institute, National Research Council of Canada, Montreal, Quebec, Canada
 - 1986-1988: Research Associate/Assistant Professor, Pittsburgh Cancer Institute, Department of Pathology and Surgery, University of Pittsburgh, Pittsburgh, PA, USA

Administrative duties

- 1991-1995 Deputy-Head, Department of Research, Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario, Canada.
- 2005-2007 Chief Scientific Officer (CSO), Bio-Quant, Inc. San Diego, CA. Responsible for organizing and hiring more than 50 scientists, post-doc fellows and technicians. Worked as a liaison between Bio-Quant, Inc. and pharmaceutical companies such as Biogen, Amgen, among many others.
 - 2008-2010 Member of hiring committee selecting candidates for the Department of Physiology, University of Oslo, Norway.

- 2010-2015 Head of hiring committee selecting candidates for the Department of Physiology, University of Oslo, Norway.
- 2016-Present Chairman, Animal care and use committee (ACUC), University of Sharjah, UAE.
- 2016-2018 Chairman, Research committee, University of Sharjah, UAE.
- 2018-Present Assistant Dean for Graduate Studies, College of Medicine, University of Sharjah.

Community Services:

2016. Supervised the Thalassemia project for third year medical students at University of Sharjah which won the number one prize (Attached).

Invited speakers

- Invited to speak in more than 40 scientific conferences and meetings of various societies.
- Chairman of the "NK AND CANCER" session in the 8th annual meeting of the society of natural immunity and 20th international natural killer cell workshop (The Netherlands, 2004).
- Chairman of "NK cell chemotaxis" session in 4th Nordic NK cell workshop (Norway, 2007).

Organization of scientific meetings

- Organized the 5th Framework European Community "Innate immunity and vaccine development" meeting, September 2003.

Membership in the European Community Framework Consortia

- Member of the 5th EC framework consortium Innate Immunity and Vaccine Development: Role of Soluble Mediators (INVADERS).
- Member of the steering committee of the 6th EC framework (CHEMCANC) program.

Patent Applications

- MONOMETHYL- AND DIMETHYLFUMARATE FOR NK CELL ACTIVATION
Inventors: MAGHAZACHI, Azzam A
Application Number: EP2015/054202

Grants Obtained

- 1988-1995 Several Grants from Canada
- 1995-2004 Several Grants from Norwegian Cancer Society and Norwegian Research Council.
- 2000-2004 Receiver of European Community consortium grant Fifth Framework Innate Immunity and Vaccine Development: Role of Soluble Mediators (INVADERS).
- 2008-2015 Supported by Biogen-Idec
- 2008-2015 Supported by TEVA-Europe
- 2016-Present Several grants from University of Sharjah
- 2019-Present Terry Fox Foundation. UAE/Canada

Supervision of Medical students

2008- 2014 Dr. Johannes Rolin, Department of Physiology, University of Oslo, Norway. Dr. Rolin did his research as medical student under my supervision and he received PhD also under my supervisions. He published more than 7 papers during his tenure with me.

2010-2014. Dr. Run Hoglund. Department of Physiology, University of Oslo, Norway. Dr. Hoglund did his research under my supervision while a medical student. He published 3 papers during his tenure with me.

2016-2017. Esra El-Arabi, Sara Adam and Abdulla Malik. Obtained the Boehringer Ingelheim grant and worked under my supervision.

2017-2018. Reem Maher Nasser, Leena Alhusari. Obtained the Boehringer Ingelheim grant and worked under my supervision.

Supervision of graduate students

1995-1999: Ala Al-Aoukaty, PhD degree, University of Oslo, Norway.

1998-2001: Marit Inngjerdingen, PhD degree, University of Oslo, Norway.

2001-2006: Yixin Jin, PhD degree, University of Oslo, Norway.

2003-2005: Devrim Oz, PhD degree, University of Marmara, Turkey. Devrim did her scientific work in my laboratory at the University of Oslo, and received her Ph.D. from the University of Marmara in Istanbul.

2007-2016: Johannes Rolin, MD/PhD, University of Oslo, Norway.

2009-2015: Rune A. Høglund, MD/PhD, University of Oslo, Norway.

2011-2016: Zaidoon Al-Jaderi, PhD, University of Oslo, Norway.

2016-Present Noha Elemam, PhD student, College of Medicine, University of Sharjah, UAE

2017-Present Mena Al-Ani, PhD student, College of Medicine, University of Sharjah, UAE

2018-Present Israa Shihab, PhD student, College of Medicine, University of Sharjah, UAE

Supervision of post-doctoral fellows

- 1999-2001: Dr. Ala Al-Aoukaty University of Oslo, Norway
- 2002-2009: Dr. Eirunn Knudsen University of Oslo, Norway
- 2005-2007: Dr. Amin Al-Shami Bio-Quant, Inc., San Diego, CA
- 2005-2007: Dr. Chnatle Bergertra Bio-Quant, Inc., San Diego, CA
- 2006-2007: Dr. Yuan Shao Bio-Quant, Inc., San Diego, CA
- 2006-2007: Dr. Wenying Zhang Bio-Quant, Inc., San Diego, CA
- 2006-2007: Dr. Ying Wen Bio-Quant, Inc., San Diego, CA
- 2006-2007: Dr. Cheng Li Bio-Quant, Inc., San Diego, CA

International Experience

Canada

USA

Europe

Publications

1. Muhammad JS, Jayakumar MN, Elemam NM, Venkatachalam T, Raju TJ, Hamoudi RA, **Maghazachi AA**. Gasdermin D hypermethylation inhibits pyroptosis and LPS-induced IL-1 β release from NK lymphoma cells. *ImmunoTargets and Therapy*, In press, 2019.
2. Elemam NM, Al-Jaderi Z, Hachim MY, **Maghazachi AA**. HCT-116 Colorectal Cancer Cells Secrete Chemokines Which Induce the Chemoattraction and Intracellular Calcium Mobilization in NK92 Cells. Influence of Dimethyl Fumarate and Monomethyl Fumarate. *Cancer Immunol. Immunother.* 68: 883-895, 2019.
3. Hachim MY, Elemam NM, **Maghazachi AA**. The Beneficial and Debilitating Effects of Environmental and Microbial Toxins, Drugs, Organic Solvents and Heavy Metals on the Onset and Progression of Multiple Sclerosis. *Toxins (Basel)*. 2019 Mar 5;11(3). pii: E147. doi: 10.3390/toxins11030147, 2019.
4. Elemam NM, Hannawi S, **Maghazachi AA**. Innate Lymphoid Cells (ILCs) as Mediators of Inflammation, Release of Cytokines and Lytic Molecules. *Toxins* 2017, 9(12), 398; doi:10.3390/toxins9120398.
5. **Maghazachi AA**. Editorial: Immunomodulatory Effects of Drugs for Treatment of Immune-Related Diseases. *Front Immunol.* 2017 Aug 11;8:969. doi: 10.3389/fimmu.2017.00969, 2017.
6. **Maghazachi AA**, Al-Jaderi Z, Sand KL. Glatiramer acetate, dimethyl fumarate and monomethyl fumarate up-regulate the expression of CCR10 on the surface of natural killer cells and enhance their chemotaxis and cytotoxicity. *Front Immunol.* 19 October 2016 doi.org/10.3389/fimmu.2016.00437, 2016.
7. Al-Jaderi Z, **Maghazachi AA**. Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases.. *Front Immunol.* 2016 Jul 22;7:278. doi: 10.3389/fimmu.2016.00278, 2016.
8. Dash NR, **Maghazachi AA**. BCG Vaccine – Beginning of its End. *MOJ Immunol* 3(2): 00085. DOI: 10.15406/moji.2016.03.00085, 2016.
9. Vego H, Sand KL, Høglund RA, Fallang LE, Gundersen G, Holmøy T, **Maghazachi AA**. Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. *Cell Mol Immunol* 13: 57-64, 2016.
10. Dash NR, **Maghazachi AA**. Dengue Vaccine an Optimistic Beginning. *MOJ Immunol* 4(1): 00112. DOI: 10.15406/moji.2016.04.00112, 2016.
11. Guimei MM, Barqawi HJ, Dash NR, **Maghazachi AA**. Sepsis- The Dilemma Continues. *MOJ Immunol* 4(3): 00125. DOI: 10.15406/moji.2016.04.00125, 2016.
12. Al-Jaderi Z, **Maghazachi AA**. Vitamin D₃ and monomethyl fumarate enhance natural killer cell lysis of dendritic cells and ameliorate the clinical score in mice suffering from experimental autoimmune encephalomyelitis (EAE). *Toxins* 7: 4730-4744, 2015.
13. Baysa A, **Maghazachi A**, Sand KL, Campesan M, Zaglia T, Mongillo M, Giorgio M, Di Lisa F, Mariero LH, Vaage J, Valen G, Stensløkken KO. Functional link between TLR9 and ShcA proteins after myocardial infarction. *Cardiovascular Research*. DOI: <http://dx.doi.org/10.1093/cvr/cvu082.77> S24 First published online: 27 June 2014.
14. Rolin J, Vego H, **Maghazachi AA**. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CCR9 and CXCR4 and

- abrogate the release of IL-6 in human monocytes. *Toxins* (Basel). 6: 2840-2856. doi: 10.3390/toxins6092840, 2014.
15. Høglund RA, **Maghazachi AA**. Multiple sclerosis and the role of immune cells. *World J. Exp. Med.* 4: 27-37, 2014.
 16. Rolin J, Maghazachi AA. Chemokine receptors and inflammatory lipids. Implications for atherosclerosis. *J. Leukoc. Biol.* 95: 575-585, 2014.
 17. Rolin J, **Maghazachi AA**. Implications of chemokine receptors and inflammatory lipids in cancer. *ImmunoTargets and Therapy.* 3: 9-18, 2013.
 18. Al-Jaderi Z, **Maghazachi AA**. Effects of Vitamin D₃, Calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. *Toxins.* 5: 1932-1947, 2013.
 19. Sand KL, Flatebo T, Andersen MB, **Maghazachi AA**. Effects of exercise on leukocytosis and blood hemostasis in 800 healthy young females and males. *World J. Exp. Med.* 2013 3(1): 11-20, 2013.
 20. Høglund R, Harbo HF, Holmøy T, **Maghazachi AA**. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate. *PLoS One* 8(4): e62237, 2013.
 21. **Maghazachi AA**. On the role of natural killer cells in neurodegenerative diseases. *Toxins* 5: 363-375, 2013.
 22. Rolin J, Al-Jaderi Z, **Maghazachi AA**. Oxidized lipids and lysophosphatidylcholine induce the chemotaxis and intracellular calcium influx in natural killer cells. *Immunobiology* 218: 875-883, 2013.
 23. **Maghazachi AA**. Role of natural killer cells in multiple sclerosis. *ISRN Immunology*, 2012:article ID 795075, doi:10.5402/2012/795075, 2012.
 24. Troitskaya M, Baysa A, Vaage J, Sand KL, **Maghazachi AA**, Valen G. Interleukin-17 (IL-17) expression is reduced during acute myocardial infarction: role on chemokine receptor expression in monocytes and their in vitro chemotaxis towards chemokines. *Toxins* 4: 1427-1439, 2012.
 25. Pandya A, Høglund RA, Holmøy T, Harbo HF, Norgauer J, **Maghazachi AA**. Identification of human NK17/NK1 cells. *PLoS One* 6(10):e26780, 2011. (
 26. Rolin J, **Maghazachi AA**. Effects of Lysophospholipids on Tumor Microenvironment. *Cancer Microenvironment* 4: 393-403, 2011.
 27. Høglund R, Hestvik ALK, Holmøy T, **Maghazachi AA**. Expression and functional activity of chemokine receptors in glatiramer acetate (GA)-specific T cells isolated from MS patient receiving the drug GA. *Human Immunol.* 72: 124-134, 2011.
 28. **Maghazachi AA**. Role of chemokines in the biology of natural killer cells. *Curr. Topics Microbiol. Immunol.* 341: 37-58, 2010.
 29. Truta-Feles K, Lagadari M, Berod L, Cubillos S, Piehler S, Herouy Y, Barz D, K, **Maghazachi AA**, Norgauer J. A novel role for histamine as a modulator of $\gamma\delta$ T cell migration and cytotoxicity: involvement of Gi and Gs protein-coupled signaling pathways. *Br. J. Pharmacol.* 161: 1291-1300, 2010.
 30. Rolin J, Sand KL, Knudsen E, **Maghazachi AA**. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. *Cancer Immunol. Immunother.* 59: 575-586, 2010.
 31. Lagadari M, Truta-Feles K, Lehmann K, Berod L, Ziemer M, Idzko M, Barz D, Kamradt T, **Maghazachi AA**, Norgauer J. Lysophosphatidic acid inhibits the

- cytotoxic activity of NK cells: involvement of Gs protein-mediated signaling. *Int. Immunol.* 21: 667-677, 2009.
32. Sand KL, Rolin J, Knudsen E, Al-Falahi Y, **Maghazachi AA**. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. *Cell. Mol. Life Sci.* 66: 1446-1456, 2009.
 33. Al-Falahi Y, Sand KL, Knudsen E, Damaj BB, Rolin J, **Maghazachi AA**. Splenic natural killer cell activity in two models of experimental neurodegenerative diseases. *J. Cell. Mol. Med* 13: 2693-2703, 2009.
 34. Lagadari M, Lehmann K, Ziemer M, Truta-Feles K, Bero L, Idzko M, Barz D, Kamradt T, **Maghazachi AA**, Norgauer J. Sphingosine-1-phosphate inhibits the cytotoxic activity of NK cells via G_s protein-mediated signaling. *International J. Oncology* 34: 287-288, 2009.
 35. Nuhaily S, Damaj BB, **Maghazachi AA**. Oxazolone-Induced Delayed Type Hypersensitivity Reaction in the Adult Yucatan Pigs. A Useful Model for Drug Development and Validation *Toxins* 1: 25-36, 2009. doi:10.3390/toxins1010025.
 36. Damaj BB, Bacerra C, Esber HJ, Wen Y, **Maghazachi AA**. Functional expression of histamine H4 receptor in human natural killer cells, monocytes, and dendritic cells. *J. Immunol.* 179: 7907-7915, 2007.
 37. Oz-Arslan D, Rüscher W, Myrtek D, Ziemer M, Jin Y, Damaj BB, Sorichter S, Idzko M, Norgauer J, **Maghazachi AA**. IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids. *J. Leukoc. Biol.* 80: 287-97, 2006.
 38. Jin Y, Damaj B, **Maghazachi AA**. Human resting CD16⁻, CD16⁺ and IL-2⁻, IL-12, IL-15⁻ or IFN- α -activated natural killer cells differentially respond to sphingosylphosphorylcholine, lysophosphatidylcholine and platelet-activating factor. *Eur. J. Immunol.* 35: 2699-2708, 2005.
 39. **Maghazachi AA**. Insights into seven and single transmembrane spanning domain receptors and their signaling pathways in human natural killer cells. *Pharmacol. Rev.* 57: 339-357, 2005.
 40. **Maghazachi AA**. Compartmentalization of human natural killer cells. *Mol. Immunol.* 42: 523-529, 2005.
 41. Gauzzi, MC, Purificato C, Donato K, Jin Y, Wang L, **Maghazachi AA**, Belardelli F, Adorini L, Gessani S. Suppressive effects of 1 α ,25-dihydroxyvitamin D₃ on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. *J. Immunol.* 174: 270-276, 2005.
 42. **Maghazachi, AA**, Knudsen E, Jin Y, Jenstad M, Chaudhry FA: D-galactosyl- β -1'-1' sphingosine and D-glucosyl- β -1'-1' sphingosine induce human natural killer apoptosis. *Biochem. Biophys. Res. Commun.* 320: 810-815, 2004.
 43. **Maghazachi, AA**: Heptahelical receptors in lymphocytes as targets for therapeutic intervention. *Drug Design Reviews-Online* 1: 195-202, 2004.
 44. Wang L, Knudsen E, Jin Y, Gessani S, **Maghazachi AA**: Lysophospholipids and chemokines induce distinct signal transduction pathways in T helper 1 and T helper 2 cells. *Cell. Signal.* 16: 991-1000, 2004.
 45. **Maghazachi AA**: G protein-coupled receptors in natural killer cells. *J. Leukoc. Biol.* 74: 16-24, 2003.
 46. Jin Y, Knudsen E, Wang L, Bryceson, Y, **Maghazachi AA**: Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization. *Eur. J. Immunol.* 33: 2083-2089, 2003.
 47. Jin Y, Knudsen E, Wang L, Bryceson Y, Damaj B, Gessani S, **Maghazachi AA**: Sphingosine 1-phosphate is a novel inhibitor of T cell proliferation. *Blood*

- 101: 4909-4915, 2003.
48. Kveberg L, Bryceson Y, Inngjerdingen M, Rolstad B, **Maghazachi AA**: Sphingosine 1 phosphate induces the chemotaxis of natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. *Eur. J. Immunol.* 32: 1856-1864, 2002.
 49. Inngjerdingen M, Torgersen KM, **Maghazachi AA**: Lck is required for stromal-derived factor (CXCL12)-induced lymphoid cell chemotaxis. *Blood* 99: 4318-4325, 2002.
 50. **Maghazachi AA**: Chemokines and Cancer. Book Review. *Cell Biology International.* 26: 129, 2002.
 51. Inngjerdingen M, Damaj B, **Maghazachi AA**: Expression and regulation of chemokine receptors in human natural killer cells. *Blood* 97: 367-375, 2001.
 52. Inngjerdingen M, Damaj B, **Maghazachi AA**: Human NK cells express chemokine receptors 4 and 8, and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine and I-309. *J. Immunol.* 164: 4048-4054, 2000.
 53. Molet S, Furukawa K, **Maghazachi AA**, Hamid Q, Giaid A: Chemokine and cytokine-induced expression of endothelin-1 and its converting enzyme-1 in endothelial cells. *J. Allergy Clin. Immunol.* 105: 333-338, 2000.
 54. **Maghazachi AA**: Chemokines, G proteins and natural killer cells. *Arch. Immunol. Ther. Exp.* 48: 65-72, 2000.
 55. **Maghazachi AA**: Signaling events at the leading edge of migrating cells. *Int. J. Biochem. Cell Biol.* 32: 931-943, 2000.
 56. Inngjerdingen M, Al-Aoukaty A, Damaj B, **Maghazachi AA**: Differential utilization of cyclic ADP-ribose pathway by chemokines to induce the mobilization of intracellular calcium in NK cells. *Biochem. Biophys. Res. Commun.* 262: 467-472, 1999.
 57. Al-Aoukaty A, Rolstad B, **Maghazachi AA**: Recruitment of pleckstrin and phosphoinositide 3-kinase γ into the cell membranes, and their association with G $\beta\gamma$ after activation of natural killer cells with chemokines. *J. Immunol.* 162: 3249-3255, 1999.
 58. **Maghazachi AA**: Intracellular signalling pathways induced by chemokines in natural killer cells. *Cell. Signal.* 11: 385-390, 1999.
 59. Al-Aoukaty A, Rolstad B, Giaid A, **Maghazachi AA**: MIP-3 α , MIP-3 β and fractalkine induce the locomotion and the mobilization of intracellular calcium, and activate the heterotrimeric G proteins in human natural killer cells. *Immunology* 95: 618-624, 1998.
 60. **Maghazachi AA**, Al-Aoukaty A: Chemokines activate natural killer cells through heterotrimeric G-proteins: implications for the treatment of AIDS and cancer. *FASEB J.* 12: 913-924, 1998.
 61. Al-Aoukaty A, Rolstad B, **Maghazachi AA**: Functional coupling of NKR-P1 receptors to various heterotrimeric G proteins in IL-2-activated natural killer cells. *J. Biol. Chem.* 272: 31604-31608, 1997.

62. **Maghazachi AA**: Role of the heterotrimeric G proteins in stromal derived factor-1 α -induced natural killer cell chemotaxis and calcium mobilization. *Biochem. Biophys. Res. Commun.* 236: 270-274, 1997.
63. **Maghazachi AA**, Skålhegg BS, Rolstad B, Al-Aoukaty A: Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and the mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and insensitive G proteins. *FASEB J.* 11: 765-774, 1997.
64. Knudsen E, Seierstad T, Naper C, Vaage JT, Benestad HB, Rolstad B, **Maghazachi AA**: Cloning, functional activities and in vivo tissue distribution of rat NKR-P1⁺TCR- $\alpha\beta$ ⁺ cells. *Int. Immunol* 9: 1043-1051, 1997.
65. Saleh D, Furukawa K, Tsao M-S, **Maghazachi AA**, Corrin B, Yanagisawa M, Barnes PJ, Giaid A: Elevated expression of endothelin-1 and endothelin converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. *Am. J. Respir. Cell Mol. Biol.* 16: 187-193, 1997.
66. **Maghazachi AA**, Al-Aoukaty A, Naper C, Torgersen KM, Rolstad B: Preferential involvement of G_o and G_z proteins in mediating rat NK cell lysis of allogeneic and tumor target cells. *J. Immunol.* 157: 5308-5314, 1996.
67. Al-Aoukaty A, Schall TJ, **Maghazachi AA**: Differential coupling of CC chemokine receptors to multiple heterotrimeric G proteins in human interleukin-2-activated natural killer cells. *Blood* 87: 4255-4260, 1996.
68. **Maghazachi AA**, Al-Aoukaty A, Schall TJ: CC chemokines induce the generation of killer cells from CD56⁺ cells. *Eur. J. Immunol.* 26: 315-319, 1996.
69. Al-Aoukaty A, Giaid A, **Maghazachi AA**: IL-8 induces calcium mobilization in IL-2-activated NK cells in the absence of inositol 1,4,5 trisphosphate. *Ann. New York Academy of Sciences* 766: 292-295, 1995.
70. **Maghazachi AA**, Al-Aoukaty A, Schall TJ: C-C Chemokines induce the chemotaxis of natural killer and IL-2-activated natural killer cells. Role for G proteins. *J. Immunol.* 153: 4969-4977, 1994.
71. Ho AD, Maruyama M, **Maghazachi AA**, Mason JR, Gluck S, Corringham RET: Soluble CD4, soluble CD8, soluble CD25, lymphopoietic recovery and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. *Blood* 84: 3550-3557, 1994.
72. **Maghazachi AA**, Al-Aoukaty A: G_s is the major G protein involved in interleukin-2-activated natural killer (IANK) cell mediated cytotoxicity. Successful introduction of anti-G protein antibodies inside streptolysin O permeabilized IANK cells. *J. Biol. Chem.* 269: 6796-6802, 1994.
73. Al-Aoukaty A, Giaid A, Sinoff C, Ho AD, **Maghazachi AA**: Priming effects of GM-CSF are coupled to cholera toxin-sensitive guanine nucleotide binding proteins in human T lymphocytes. *Blood* 83: 1299-1309, 1994.
74. Sebok K, Woodside D, Al-Aoukaty A, Ho AD, **Maghazachi AA**: IL-8 induces the locomotion of human IL-2-activated natural killer cells. Involvement of a guanine nucleotide binding (G_o) protein. *J. Immunol.* 150: 1524-1534, 1993.

75. Phillips-Quagliata JM, Rao TD, **Maghazachi AA**, Faria AMC, Basch RS: The IgA receptors of T560, a murine IL-4-secreting, CD5⁻, IgGAK⁺, BrMRBC binding B lymphoma. *Ann. New York Academy of Sciences* 651: 491-493, 1992.
76. Rao TD, **Maghazachi AA**, Gonzalez AV, Phillips-Quagliata JM: A novel IgA receptor expressed on a murine B cell lymphoma. *J. Immunol.* 149: 143-153, 1992.
77. Rao TD, **Maghazachi AA**, Faria AMC, Basch RS, Phillips-Quagliata JM: T560: an (H-2^b X H-2a^a) F₁ hybrid, phosphorylcholine (PC)-binding, murine B cell lymphoma that bears receptors for IgA and IgG, presents antigen and secretes IL-4. *Int. Immunol* 4: 107-118, 1992.
78. **Maghazachi AA**: Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells. *Cancer Immunol. Immunother.* 35: 426-427, 1992.
79. **Maghazachi AA**: Tumor necrosis factor-alpha is chemokinetic for lymphokine-activated killer cells: regulation by cyclic adenosine monophosphate. *J. Leukoc. Biol.* 49: 302-308, 1991.
80. Phillips-Quagliata JM, Rao TD, **Maghazachi AA**, Gonzalez A, Faria AM: Sensitivity of receptors for IgA on T560, a murine B lymphoma to phorbol myristate acetate (PMA) and to phosphatidylinositol-specific phospholipase C (PIPLC). *Immunologic Res.* 10: 432-436, 1991.
81. **Maghazachi AA**, Fitzgibbon L: Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers. *Cancer Immunol. Immunother.* 31: 139-145, 1990.
82. **Maghazachi AA**: Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors. *Immunology* 70: 465-472, 1990.
83. **Maghazachi AA**: Insulin-like growth factor 1 and insulin augment interleukin-2 or interleukin-2 plus concanavalin A-induced T cell proliferation. In "*Molecular and Cellular Biology of Cytokines*". Oppenheim JJ, Powanda MC, Kluger MJ, Dinarello CA (eds.). Wiley-Liss, pp.463-469, 1990.
84. **Maghazachi AA**: Interleukin-2 is central for the development of rat LAK cells: regulation by various cytokines. In "*Natural Killer Cells: Biology and Clinical Application*" Schmidt RE (ed.). Karger, Basel, pp.190-193, 1990.
85. Rao TD, **Maghazachi AA**, Phillips-Quagliata JM: A murine lymphoma with receptors for IgA. In "*Advances in Mucosal Immunology*". Challacombe SJ, Bland PW, Stokes CR, Heatley RV, McI Mowat A (eds.). Kluwer Academic Publisher, Dordrecht, pp.308-317, 1990.
86. Goldfarb RH, Kitson RP, Basse P, **Maghazachi AA**, Giffen CA, Wasserman K, McLaughlin M, Herberman RB: Proteolytic enzymes of rat adherent lymphokine-activated killer cells. In "*Natural Killer Cells: Biology and Clinical Application*". Schmidt RE (ed.). Karger, Basel, pp.259-264, 1990.
87. Sasaki A, Jain RK, **Maghazachi AA**, Goldfarb RH, Herberman RB: Low deformability of lymphokine activated killer cells as a possible determinant of in vivo distribution. *Cancer Res.* 49: 3742-3746, 1989.
88. **Maghazachi AA**, Goldfarb RH, Kitson RP, Hiserodt JC, Giffen CA, Herberman RB: Tissue distribution of IL-2 activated cells. In "*Interleukin-2 and Killer Cells*

in Cancer". Lotzova E, Herberman RB (eds.) CRC Review, Florida, pp. 259-283, 1989.

89. **Maghazachi AA**, Goldfarb RH, Herberman RB: Effect of carbohydrates on the in vivo migration of purified LAK cells. In "*Natural Killer Cells and Host Defence*". Ades EW, Lopez C (eds.). Karger, Basel, pp.242-245, 1989.
90. **Maghazachi AA**, Goldfarb RH, Herberman RB: Influence of T cells on the expression of LAK cell activity and in vivo tissue distribution. *J. Immunol.* 141: 4039-4046, 1988.
91. **Maghazachi AA**, Vujanovic NL, Herberman RB, Hiserodt JC: Lymphokine-activated killer cells in rats. IV. Developmental relationship among large agranular lymphocytes (LAL), large granular lymphocytes (LGL), and lymphokine activated killer (LAK) cells. *J. Immunol.* 140: 2846-2852, 1988.
92. **Maghazachi AA**, Herberman RB, Vujanovic NL, Hiserodt JC: In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. *Cell. Immunol.* 115: 179-194, 1988.
93. Vujanovic NL, Herberman RB, **Maghazachi AA**, Hiserodt JC: Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their conversion into lymphokine activated killer cells. *J. Exp. Med.* 167: 15-29, 1988.
94. **Maghazachi AA**, Phillips-Quagliata JM: Keyhole limpet hemocyanin-propagated Peyer's patch T cell clones that help IgA responses. *J. Immunol.* 140: 3380-3388, 1988.
95. **Maghazachi AA**, Phillips-Quagliata JM: Con A-propagated, auto-reactive T cell clones that secrete factors promoting high IgA responses. *Int. Arch. Allergy Applied Immunol.* 86: 147-156, 1988.
96. Phillips-Quagliata JM, **Maghazachi AA**: T cell clones that help IgA responses. In "*Advances in Experimental Medicine and Biology*". Mesteckey J, McGee JR, Bienenstock J, Orga PL (eds.). Plenum Press, New York, 216: 101-117, 1987.
97. Paraskevas F, Lee ST, Wang KC, **Maghazachi AA**: T cell derived factors detected in vivo six hours after immunization enhance the immune response. *Lymphokines* 9: 201-235, 1984.
98. Paraskevas F, Lee ST, **Maghazachi AA**: Anti suppression: a novel pathway in T cell regulation of B cell function. *Survey Immunol. Res.* 3: 115-121, 1984.
99. **Maghazachi AA**, Lee ST, Paraskevas F: Detection in vivo six hours after immunization of a mediator with possible anti suppressor activity. *Eur. J. Immunol.* 13: 799-803, 1983.

Ebooks:

Maghazachi AA. Immunomodulatory Effects of Drugs for Treatment of Immune-Related Diseases. Frontiers Media SA, 2017